# Contact Sermorelin Safe — Editorial Corrections & Sources

> Contact Sermorelin Safe about the GHRH(1-29) literature digest — corrections, source questions, and citations. An editorial project, not a clinic, vendor, or prescriber.

## Get in touch

Sermorelin Safe is an editorial project, and the most useful messages we receive are about the literature itself: a citation we should add, a study we read too generously or too harshly, a number that does not match its source, or a place where a finding should be re-graded. Corrections are welcome and taken seriously — the whole value of a due-diligence site is being accountable to the record.

What we cannot help with: we do not give medical advice, we do not recommend or supply sermorelin or any other compound, and we do not answer personal health or dosing questions. We are not a clinic, a pharmacy, or a prescriber. For anything about your own health, a licensed clinician who can see your full picture is the right contact — not an editorial website.

## Use the form

Use the form below for editorial and source-related messages. Tell us the page, the claim, and the source you are referring to, and we will review it against the cited literature. We read everything that points us back to a study.

---

An engineering-datasheet reading of the sermorelin record — every GHRH(1-29) figure logged to its study and stamped with an evidence grade, the proven pediatric trial kept apart from the borrowed tesamorelin numbers and both apart from the in-silico oncology and preclinical regenerative signals; no clinic behind the spec sheet and nothing here dosed, compounded, prescribed, or sold.